You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. An inhaled PDGF receptor inhibitor for the treatment of pulmonary arterial hyper

    SBC: Pulmokine, Inc.            Topic: NHLBI

    DESCRIPTION (provided by applicant): The purpose of this Phase II project is to develop a new treatment for pulmonary arterial hypertension (PAH) consisting of the inhaled platelet derived growth factor receptor (PDGFR) inhibitor PK10453. PAH is a diseaseof the pulmonary vasculature associated with high morbidity and mortality. Signaling through the PDGFR leads to smooth muscle cell proliferation ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  2. Promoting Responsible Drinking: An Internet-based, Interactive Computer Tailored Intervention

    SBC: Pro-Change Behavior Systems, Inc.            Topic: NIAAA

    DESCRIPTION provided by applicant Excessive alcohol use is associated with a range of serious and costly health social and economic consequences at the individual and societal level This program of research serves as a venue by which to produce and test an innovative science based and cost effective means to intervene in a private convenient and individualized way with employed adults wh ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  3. Engineered tissue-based, high-throughput compound profiling

    SBC: Invivosciences, Inc.            Topic: 300

    DESCRIPTION provided by applicant Current NIGMS SBIR funding supported InvivoSciences LLCandapos s IVS launch of several product lines in IVS generated revenues from the sales of three dimensional D cell culture tools MC TM and IVS InsertsTM that can grow various hydrogel tissues without any support layers The culture tools enable Palpator TM and Tissue StretcherTM to stretch the ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  4. Clinical Development of Non-compressible Hemostatic Agent for High-Volume Hemorrhage

    SBC: BIOMEDICA MANAGEMENT CORP.            Topic: NHLBI

    DESCRIPTION provided by applicant andquot ClotFoam R andquot is a novel adhesive sealant composition and second generation hemostatic agent This biological agent was designed to arrest moderate to severe blood loss arising from intracavitary traumatic injury or intraoperative hemorrhage without compression stitches or staples Control of Intraoperative hemorrhage in laparoscopic surgery whi ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  5. Technology Transfer of Multimodal Biometric Application Resource Kit (MBARK)

    SBC: Ad Harmony            Topic: N/A

    The technical objective of this project is to develop a prototype of a face recognition application in a cloud computing environment utilizing MBARK as the middleware. The application will have a client piece that will run on a mobile device such as a laptop and a server piece that will run on a higher-performance computing cluster. The specific objectives of this development project can be enumer ...

    SBIR Phase II 2011 Department of CommerceNational Institute of Standards and Technology
  6. Query- Based Interoperability and CAD/CAE Integration in Assemblies

    SBC: INTACT SOLUTIONS, INC            Topic: N/A

    We propose to design and implement a set of CAD queries by which to achieve model interchangeability in assemblies, model interoperability, and model integration for CAD/CAE. A model scenario will be used to illustrate how this can be accomplished. In Phase 1, we will establish the feasibility of the approach, develop high level algorithms and conduct software experiments to verify their efficienc ...

    SBIR Phase I 2012 Department of CommerceNational Institute of Standards and Technology
  7. Development of a GPU-based High Performance Community Radiative Transfer Model

    SBC: Hyper Sensing, LLC            Topic: 835D

    Computation of the radiative transfer model for a hyperspectral sounder with thousands of spectral channels is very time-consuming. Consequently, operational data assimilation systems can assimilate only a few hundred channels. The radiative transfer model is very suitable for GPU implementation to take advantage of GPU massively parallel computing capability, where radiances at various channels c ...

    SBIR Phase I 2011 Department of CommerceNational Oceanic and Atmospheric Administration
  8. An Automated Test Bed for Assessing System-of-System (SoS) Assurance

    SBC: DeVivo AST, Inc.            Topic: 9040177R

    As System-of-Systems (SoS) become more complex, interactions and latent emergent behaviors become difficult to identify and control. Unmanned Autonomous Systems (UAS) are a prime example of SoS that are both critical and difficult to assure. Drawing upon prior work into multi-criteria decision making (MCDM), DeVivo AST has developed TOP Score, a software tool that facilitates the modeling and anal ...

    SBIR Phase I 2011 Department of CommerceNational Institute of Standards and Technology
  9. Lab on a chip point of care assay for the rapid serodiagnosis of Lyme disease

    SBC: BIOPEPTIDES CORP            Topic: NIAID

    DESCRIPTION (provided by applicant): Caused by Borrelia burgdorferi, Lyme Disease (LD) can affect the skin, heart, joints or nervous system leading to an array of symptoms that overlap with those of other illnesses. LD is the most common vector-borne infectious disease in the United States and remains a significant public health concern. Early diagnosis and treatment is key to improving disease ou ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  10. Safe and Efficacious Oral MIF Inhibitors for Rheumatoid Arthritis Treatment

    SBC: INNOVIMMUNE BIOTHERAPEUTICS, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): There are high unmet medical needs in the limited biologic therapeutics for 1.0% of adults with rheumatoid arthritis [RA] associated with staggering 39.2 billion annual US health care and societal costs. These are dueto inadequate efficacy; patient's inconvenience, prohibitive costs, poor adherence and treatment discontinuations; manufacturing risks and s ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government